Published in Blood Weekly, December 20th, 2001
Dr. John K. Hayes and colleagues at the University of Virginia Health System in Charlottesville and the University of Utah School of Medicine in Salt Lake City evaluated the safety profile of rHb1.1 in anesthetized patients.
Although rHb1.1 administration triggered some unexplained symptoms, their clinical relevance seems to be minimal, they said.
Hayes and coauthors examined data from 18 rHb1.1-treated patients undergoing elective surgery under general...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2001-12-20)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.